Last $31.62 USD
Change Today +1.46 / 4.84%
Volume 1.5M
ISIS On Other Exchanges
As of 4:30 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $62.66
52 Week Low
05/9/14 - $22.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

isis pharmaceuticals inc (ISIS) Related Businessweek News

No Related Businessweek News Found

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

365 Employees
Last Reported Date: 03/3/14
Founded in 1989

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $581.4K
Chief Operating Officer, Corporate Secretary,...
Total Annual Compensation: $1.2M
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Senior Vice President of Development
Total Annual Compensation: $624.4K
Compensation as of Fiscal Year 2013.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-APO(a)(Rx) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)(Rx) is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a). Isis plans to develop ISIS-APO(a)(Rx) to treat patients with high Lp(a) levels who are at high risk of experiencing life-threatening cardiovascular events. The Phase 2 study is a randomized, placebo-controlled, dose-titration study evaluating the safety and efficacy of ISIS-APO(a)(Rx). The 12 week study will evaluate 100 mg, 200 mg and 300 mg doses of ISIS-APO(a)(Rx) in approximately 60 patients with Lp(a) levels of 50 mg/dL or greater. According to the National Institutes of Health, an average normal Lp(a) level is less than 30 mg/dL and the European Atherosclerosis Society recommends that Lp(a) levels be less than or equal to 50 mg/dL. ISIS-APO(a)(Rx) is an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis. Based on its substantial experience and expertise in developing drugs to treat a variety of lipid disorders, Isis is currently developing ISIS-APO(a)(Rx) on its own. Apolipoprotein(a) contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex called Lp(a). Currently there are no drugs on the market that can effectively lower elevated Lp(a) to recommended Lp(a) levels. Isis plans to develop ISIS-APO(a)(Rx) to treat patients with high Lp(a) levels who have either coronary heart disease or aortic stenosis. Both of these groups of patients are at high risk of cardiovascular events. ISIS-APO(a)(Rx) is part of Isis' cardiovascular disease franchise comprised of drugs that target many of the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis.

Isis Pharmaceuticals, Inc. Announces Encouraging Results from Phase II Diabetes Study

Isis Pharmaceuticals, Inc. has announced encouraging final results from its Phase II study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c (HbA1c) of up to 2.25 percentage points from baseline after only 13 weeks of treatment. Patients receiving placebo had an 0.25 percentage point reduction in HbA1c. In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent. PP patients treated with ISIS-GCGRRx in this study also achieved a mean reduction of up to 74.9 µmol/L in fructosamine. In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.

Isis Pharmaceuticals, Inc. Earns $10 Million Milestone Payment from Biogen Idec

Isis Pharmaceuticals, Inc. announced it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders and is the fourth collaboration between the two companies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $31.62 USD +1.46

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $2.96 USD +0.04
Prosensa Holding NV $9.67 USD -0.05
Regulus Therapeutics Inc $6.54 USD +0.31
Silence Therapeutics PLC 225.00 GBp +2.25
Tekmira Pharmaceuticals Corp C$12.07 CAD +1.08
View Industry Companies

Industry Analysis


Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.7x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at